Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
4 competitors in Achondroplasia
View Full LandscapeTarget Indication
Achondroplasia
Mechanism of Action
C-type Natriuretic Peptide Analog
Clinical Trial
NCT03197766Last updated: 12/3/2025
Latest Patent Expiry
Patents Listed
8
Exclusivity
Application
NDA 214938Voxzogo
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Phenylketonurias
Mucopolysaccharidosis IV A
Pain, Post-operative
Anemia Associated With End Stage Renal Disease
Hemophilia A With Inhibitor